ResMed
RMD
ResMed (RMD) earnings history
Most recent quarter
- Fiscal period
- Q4 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.95
- EPS estimate
- $2.89
- EPS surprise
- +1.98%
- Revenue surprise
- +0.16%
- Revenue
- $1.5B
- Revenue estimate
- $1.5B
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2026 | Aug 6, 2026 | $2.89 | $2.95 | +1.98% | $1.5B | SEC |
| Q3 2026 | Apr 30, 2026 | $2.80 | $2.86 | +2.31% | $1.4B | SEC |
| Q2 2026 | Jan 29, 2026 | $2.74 | $2.81 | +2.73% | $1.4B | SEC |
| Q1 2026 | Oct 30, 2025 | $2.52 | $2.55 | +1.32% | $1.3B | SEC |
| Q4 2025 | Jul 31, 2025 | $2.55 | $2.55 | +0.00% | $1.3B | SEC |
| Q3 2025 | Apr 23, 2025 | $2.38 | $2.37 | −0.34% | $1.3B | SEC |
| Q2 2025 | Jan 30, 2025 | $2.32 | $2.43 | +4.94% | $1.3B | SEC |
| Q1 2025 | Oct 24, 2024 | $2.05 | $2.20 | +7.10% | $1.2B | SEC |
| Q4 2024 | Aug 1, 2024 | $2.08 | $2.08 | −0.13% | $1.2B | SEC |
| Q3 2024 | Apr 25, 2024 | $1.93 | $2.13 | +10.51% | $1.2B | SEC |
| Q2 2024 | Jan 24, 2024 | $1.78 | $1.88 | +5.84% | $1.2B | SEC |
| Q1 2024 | Oct 26, 2023 | $1.62 | $1.64 | +1.29% | $1.1B | SEC |
| Q4 2023 | Aug 3, 2023 | $1.68 | $1.60 | −4.72% | $1.1B | SEC |
| Q3 2023 | Apr 27, 2023 | $1.61 | $1.68 | +4.65% | $1.1B | SEC |
| Q2 2023 | Jan 26, 2023 | $1.61 | $1.66 | +2.82% | $1.0B | SEC |
| Q1 2023 | Oct 27, 2022 | $1.54 | $1.51 | −1.63% | $950.3M | SEC |
| Q4 2022 | Aug 11, 2022 | $1.44 | $1.49 | +3.34% | $914.7M | SEC |
| Q3 2022 | Apr 28, 2022 | $1.46 | $1.32 | −9.45% | $864.5M | SEC |
| Q2 2022 | Jan 27, 2022 | $1.50 | $1.47 | −1.73% | $894.9M | SEC |
| Q1 2022 | Oct 28, 2021 | $1.37 | $1.51 | +10.07% | $904.0M | SEC |
Quarterly revenue
Frequently asked questions
When did ResMed (RMD) last report earnings?
ResMed last reported on Aug 6, 2026, covering fiscal Q4 2026.
Did RMD beat earnings estimates?
Yes. ResMed reported EPS of $2.95 for Q4 2026 against a $2.89 estimate — a 1.98% beat.
How much revenue did RMD report last quarter?
ResMed reported $1.5B in revenue for Q4 2026, against a consensus estimate of $1.5B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.